126 results
Page 5 of 7
8-K
EX-99.1
l5x izpvk0n
29 Sep 21
Regulation FD Disclosure
8:30am
424B5
i9k6mj
3 Sep 21
Prospectus supplement for primary offering
8:01am
8-K
EX-99.1
gskmd
2 Aug 21
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides
8:00am
8-K
EX-99.1
cafi9e3qsh b65fx
7 Jul 21
VBI Vaccines Appoints Linda Bain to Board of Directors
9:25am
8-K
EX-99.1
4mew4
1 Jul 21
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
4:34pm
8-K
EX-99.1
fu0 qqy437h9rqzpkbrf
29 Jun 21
VBI Vaccines Announces Initial Positive Phase 1 Data for its eVLP Vaccine Candidate Against COVID-19
7:35am
8-K
EX-99.1
wxl4z8bs
23 Jun 21
Regulation FD Disclosure
7:00am
8-K
EX-99.1
rqt0b46h b1h2ar
17 Jun 21
VBI Vaccines to Present at Upcoming Scientific Conferences
8:00am
8-K
EX-99.1
37rxi429 ipknyz
10 Jun 21
VBI Vaccines Announces Results of Annual General Meeting
12:00am
8-K
EX-99.1
bbe4v0t
9 Jun 21
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at About Hepatitis B
8:00am
8-K
EX-99.1
ccs zq1gy
8 Jun 21
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
8:00am
8-K
EX-99.1
jgf01r0
1 Jun 21
VBI Vaccines to Participate in Upcoming Investor Conferences
8:30am
8-K
EX-99.1
wtyr5 ur3
21 May 21
VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures
8:00am
8-K
EX-99.1
b4q5dsgkynsljumcpo
20 May 21
VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
8:00am
8-K
EX-99.1
wkr2oe4ua6uqj vlcv
12 May 21
Regulation FD Disclosure
8:00am
8-K
EX-99.1
4wo37tk
10 May 21
VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.1
nhgn6nz9wp2 w4
3 May 21
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
9:00am
8-K
EX-99.1
f2k2 cz0q
28 Apr 21
Regulation FD Disclosure
8:00am